FLJ11730 Peptide
Reactivity: Mammalian
Host: Synthetic
BP, IHC, WB
-
- Target
- FLJ11730
- Peptide Type
- Synthetic
- Origin
- Mammalian
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), Immunohistochemistry (IHC), Western Blotting (WB)
- Sequence
- HNKAAPPQIP DTRRELAELV KRKQELAETL ANLERQIYAF EGSYLEDTQM
- Characteristics
-
A synthetic peptide for use as a blocking control in assays to test for specificity of FLJ11730 antibody,
Alternative Names: FLJ11730 control peptide, FLJ11730 antibody Blocking Peptide, Anti-FLJ11730 Blocking Peptide, Hypothetical Protein FLJ11730 Blocking Peptide, Sarcoma antigen Blocking Peptide, NY-SAR-91 Blocking Peptide, CDABP0189 Blocking Peptide, NY-SAR-91FLJ11730 Blocking Peptide
-
-
- Application Notes
- Optimal conditions should be determined by the investigator
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
- Buffer
- PBS
- Handling Advice
- Avoid repeated freeze/thaw cycles.
- Storage
- -20 °C
- Storage Comment
- Store at -20 °C long term.
-
- Target
- FLJ11730
- Background
- The screening of cDNA expression libraries from human tumors with serum antibody (SEREX) has proven to be a powerful method for identifying the repertoire of tumor antigens recognised by the immune system of cancer patients, referred to as the cancer immunome. In this regard, cancer/testis (CT) antigens are of particular interest because of their immunogenicity and restricted expression patterns. Synoivial sarcomas are striking with regard to CT antigen expression, however, highly expressed in sarcoma, CT antigens do not induce frequent humoral immune responses in sarcoma patients. Sera from two patients were used to immunoscreen cDNA libraries from two synovial sarcoma cell lines and normal testis, resulting in the identification of 113 distinct antigens. Sarcoma antigen NY-SAR-91 is one of them.
- Molecular Weight
- 23 kDa
-
You are here:
